Cantargia AB
Research Cantargia AB (CANTA) on Bullrun: market cap SEK 400.36M, P/E 2.0. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCANTA
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryBiotechnology
- CurrencySEK
- Market capSEK 400.36M
- P/E2.0
- Financial periodQ1 2026
- RevenueSEK 508.00K
- Net income-SEK 32.97M
- Free cash flow-SEK 25.96M
Valuation Snapshot
latest market cap is SEK 400.36M; P/E is 2.0.
Peer valuation comparison
Latest P/E is 2x versus a Healthcare sector median of 24.61x (91.9% below).
Latest P/E is 2x versus a Sweden median of 18.18x (89.0% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 316.70M | SEK 146.98M | SEK 149.66M | n/a | 0.59 | SEK 281.82M | SEK 22.39M | SEK 265.88M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-07 | SEK 400.36M | 2.0 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 SEK.
About Cantargia AB
Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an monoclonal antibody that can bind IL1RAP, which is in phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Cantargia AB's market cap?
Cantargia AB's market capitalization is SEK 400.36M.
What is Cantargia AB's P/E ratio?
Cantargia AB's price-to-earnings (P/E) ratio is 2.0.
What does Cantargia AB do?
Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an monoclonal antibody that can bind IL1RAP, which is in phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in phase 1 clinical trial for the treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis.